New valve implant offers hope for rare heart condition
NCT ID NCT05064514
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is testing a custom-made artificial heart valve, called TRICENTO, in 15 people with carcinoid heart disease who have severe leakage of the tricuspid valve and cannot have surgery. The valve is delivered through a catheter, avoiding open-heart surgery. The goal is to see if it reduces valve leakage and improves symptoms and quality of life.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
TRICENTO valved stent graft (a custom-made artificial heart valve delivered through a catheter)
What this could lead to
If it works, this could offer a less invasive treatment option for people with carcinoid heart disease who have severe valve leakage and cannot undergo open-heart surgery.
What could go wrong
This is a very early, small study with only 15 participants, so results may not apply to everyone. The procedure carries risks like any heart implant, and the valve may not work as intended or could cause complications.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARCINOID SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Barts Health NHS Trust
London, England, E1 1BB, United Kingdom